Ace Inhibitors as good as Sacubitril/Valsartan in preventing CV events in MI with HF
Sacubitril/valsartan, the heart failure drugs did not significantly reduce the rate of cardiovascular death, heart failure hospitalization or outpatient heart failure requiring treatment in patients following acute myocardial infarction (AMI) compared with the ACE inhibitor ramipril, suggests a study presented at the American College of Cardiology's 70th Annual Scientific Session on May 15, 2021.
Previous studies have shown that the combination of sacubitril and valsartan was more beneficial than an ACE inhibitor for patients with symptomatic heart failure and reduced ejection fraction. To further evaluate the superiority of sacubitril and valsartan combination, Dr Marc Pfeffer and his team conducted a first large trial to examine whether sacubitril/valsartan can reduce heart failure and associated hospitalizations and deaths in patients post-heart attack who face a high risk of developing heart failure.
The PARADISE-MI trial was a multi-centre, randomized, double-blind, active-controlled, parallel-group phase 3 study. The researchers included a total of 5661 patients at high risk of cardiovascular death and heart failure and randomized them to receive sacubitril-valsartan 97 mg-103 mg twice a day (n = 2830) or the ACE inhibitor ramipril 5 mg twice a day (n = 2831). The patients were followed for 23 months. The primary endpoints of the study was a composite of cardiovascular death, heart failure hospitalization or the development of symptomatic heart failure. Secondary endpoints included cardiovascular death or first heart failure hospitalization.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.